日本精品网站在线_国产91免费观看_国产激情对白一区二区三区四_国产野战无套av毛片_中文字幕人妻侵犯视频_91茄子在线观看_最新无码视频_激情五月天色综合_久久久无码精品亚洲日韩日韩?v_歐美精品自拍偷拍

Integrity,Innovation,Reliability,Responsibility

Hinova's Clinical Trial Application of HP558 for the Treatment of gastrointestinal Tumors was Accepted by NMPA

Time:2021-09-14 Source:海創(chuàng)藥業(yè) Hits:2583

On September 7, 2021, Hinova Pharmaceuticals Inc., a clinical-stage biopharmaceutical company focused on developing novel therapeutics for cancers and metabolic diseases through targeted protein degradation technologies, announced that the National Medical Products Administration (NMPA) had accepted its application for clinical trials of HP558 injection.

HP558 is a First-in-class CD44v6 inhibitor developed by Amcure GmbH in Germany and licenced by Hinova. Hinova has exclusive rights to develop and commercialize HP558 in China (including Hong Kong, Macao and Taiwan) for all indications.

The Phase I clinical trial of HP558 has been completed in Europe, and no drugs with the same target for the same indication have entered clinical trials worldwide. Preclinical and clinical trials have shown that HP558 has good antitumor activity, safety and tolerability, and has potential therapeutic effects in gastrointestinal tumors. It can also be used in combination with chemotherapy or other target therapy agents for the treatment of a variety of advanced tumors. 


About Hinova

Hinova is an international and clinical-stage biopharmaceutical company focused on developing novel therapeutics for cancers and metabolic diseases. Hinova has committed to the discovery and development of innovative medicines for patients globally through deuteration and targeted protein degradation technologies.